Umbilical cord blood stem cells: Implications for cardiovascular regenerative medicine

Jonathan L. Goldberg, Mary J. Laughlin, Vincent J. Pompili

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


The treatment of cardiovascular disease has benefited from advances in pharmacologic and intravascular intervention reducing the morbidity and mortality associated with this disease. To address the need in managing clinically complex vascular disease with limited therapeutic options studies have focused on cellular therapy as a means to augment compensatory mechanisms and to potentially prevent escalation and advancement of disease. Umbilical cord blood (UCB) is a rich source of hematopoietic stem cells (HSC) and thus may be a potential source of cells for this type of therapy. UCB can be collected at no risk to the donor, is immediately available, has a wider availability of HLA phenotypes with a possible lower immune reactivity and does not provoke ethically charged debates. Moreover, stem cells isolated from patients with chronic disease have impairment of their reparative abilities thus limiting their therapeutic impact. The potential of UCB HSC in augmenting this process has been studied extensively both in vitro and in vivo and has shown a benefit in acute and chronic vascular ischemia. Although studies suggest efficacy with no obvious safety concerns the mechanism for this therapeutic effect is unknown.

Original languageEnglish (US)
Pages (from-to)912-920
Number of pages9
JournalJournal of Molecular and Cellular Cardiology
Issue number5
StatePublished - May 2007


  • Angiogenesis
  • Cardiovascular disease
  • Hematopoietic stem cell
  • Regenerative medicine
  • Umbilical cord blood

ASJC Scopus subject areas

  • Molecular Biology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Umbilical cord blood stem cells: Implications for cardiovascular regenerative medicine'. Together they form a unique fingerprint.

Cite this